Results 191 to 200 of about 18,575 (296)

Adverse events related to neuromuscular blocking agents: a disproportionality analysis of the FDA adverse event reporting system. [PDF]

Front Pharmacol
Li L, Xu Q, Liu Y, Pang L, Cui Z, Lu Y.
europepmc   +1 more source

INFLUENCE OF “PRIMING” ON THE POTENCY OF NON-DEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS

, 1987
Marissa Brady, R. K. Mirakhur, F. M. Gibson   +2 more
openalex   +1 more source

Tracheal Intubation Without the Use of Neuromuscular Blocking Agents[DOI: 10.5812/aapm.3478] [PDF]

, 2012
Smita Prakash
openalex   +1 more source

The Calcium‐Binding Protein S100A10 (p11) Is Required for Normal Motor Performance by Regulating Vesicle Dynamics at Excitatory Synapses

Acta Physiologica, Volume 242, Issue 2, February 2026.
ABSTRACT Aim Identifying interactors in sensorimotor processing and neurotransmission remains a current challenge for understanding neural information processing and brain function. Methods To evaluate the role of p11 in sensorimotor processing and excitatory synaptic neurotransmission, neuron‐specific lentivirus‐directed p11 silencing, small ...
Esther Vilches‐Herrando, Guillermo Rodríguez‐Bey, Rosendo G. Hernández, Ángela Gento‐Caro, Ángel M. Pastor, Antonio Campos‐Caro, David González‐Forero, Bernardo Moreno‐López   +7 more
wiley   +1 more source

Management of Neuromuscular Blocking Agents in Critically Ill Patients with Lung Diseases. [PDF]

J Clin Med
Iavarone IG, Al-Husinat L, Vélez-Páez JL, Robba C, Silva PL, Rocco PRM, Battaglini D.   +6 more
europepmc   +1 more source

Early neuromuscular blocking agents for adults with acute respiratory distress syndrome: a systematic review, meta-analysis and meta-regression. [PDF]

BMJ Open, 2020
Shao S, Kang H, Tong Z.
europepmc   +1 more source

Cardiovascular effects of neuromuscular blocking agents in unanestbetized dogs

, 1975
Akira Ueno, Kazuko Nonaka, K Konno
openalex   +1 more source

Pharmacological intervention: Challenges and promising outcomes for fat loss and preservation of lean body mass in the treatment of overweight and type 2 diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 803-816, February 2026.
Abstract Treatment with GLP‐1 receptor agonists (GLP‐1 RAs) is effective in reducing body weight in individuals with overweight and type 2 diabetes (T2D). However, measurements indicate that a considerable portion of the weight loss derives from fat‐free mass (FFM), including skeletal muscle, which may compromise metabolic health and physical function.
Viktor Aimelet, Jens Juul Holst
wiley   +1 more source

"Thrombolysis" by a neuromuscular blocking agent [PDF]

, 2006
Patrizio Pascale, B. Quartenoud
openalex   +1 more source